Skip to main content
Research_

Cardiometabolic disease

Committed to help prevent diabetes, fatty liver, and other obesity-driven disease.

Our aim is to discover novel markers, effectors, and predictors of cardiometabolic disease, which refers to the nexus of cardiovascular disease and obesity-driven diseases like type 2 diabetes.

Our vision

Our aim is to discover novel markers, effectors, and predictors of cardiometabolic disease, which refers to the nexus of cardiovascular disease and obesity-driven diseases like type 2 diabetes.

Our work

Obesity-driven metabolic diseases are the major drivers of atherosclerotic cardiovascular disease in the modern era. Our mission is to discover better diagnostic markers, predictors, and therapies for cardiometabolic disease. Our work is closely aligned with the mission of the Charles Perkins Centre, therefore we have many great collaborators based at the centre that help elevate our work.

What impact will this research have?

We have discovered a number of markers of cardiometabolic disease that also predict disease far into the future. For example, we have recently identified a new circulating biomarker that is an independent predictor of diabetes over a decade before diagnosis. We are now investigating therapies targeting these pathways.

Featured research projects

Collaboration team

  • Dr Yen Chin Koay

Group Lead

Dr John O'Sullivan
I fulfill my mission in world-class facilities. My collaborators at the centre enhance my research by providing allied expertise in closely related fields.
Read about John O'Sullivan